Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYLD Antibodies:
anti-Mouse (Murine) CYLD Antibodies:
anti-Rat (Rattus) CYLD Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal CYLD Primary Antibody for ELISA, WB - ABIN188848
Massoumi, Chmielarska, Hennecke, Pfeifer, Fässler: Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. in Cell 2006
Cow (Bovine) Polyclonal CYLD Primary Antibody for ICC, IF - ABIN410065
Wu, Mu, Gao, Wang, Sy, Li: Prion protein is required for tumor necrosis factor α (TNFα)-triggered nuclear factor κB (NF-κB) signaling and cytokine production. in The Journal of biological chemistry 1970
Human Polyclonal CYLD Primary Antibody for ICC, IF - ABIN252428
Moranta, Regueiro, March, Llobet, Margareto, Larrarte, Larrate, Garmendia, Bengoechea: Klebsiella pneumoniae capsule polysaccharide impedes the expression of beta-defensins by airway epithelial cells. in Infection and immunity 2010
Low expression of CYLD is associated with glioma.
theses data show that CYLD regulates the magnitude of ubiquitination of several major effectors of the EGFR (show EGFR Antibodies) pathway by assisting the recruitment of the ubiquitin ligase Cbl-b to the activated EGFR (show EGFR Antibodies) complex.
Through deceasing the expression of Cylindromatosis (CYLD), a K63-specific DUB and endogenous blocker of NF-kappaB (show NFKB1 Antibodies) signaling, miR (show MLXIP Antibodies)-130b can in return sustain the persistent activation of NF-kappaB (show NFKB1 Antibodies), which may promote the malignant progression of transitional cell carcinoma of bladder.
While previous reports have described CYLD as a regulator of DVL proteins; this data suggests the presence of a more complicated reciprocal regulatory mechanism in CML cell lines.
Thrombin (show F2 Antibodies)-mediated MALT1 (show MALT1 Antibodies) protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage.
MiR (show MLXIP Antibodies)-767 acted as a role of tumor promoter by targeting CYLD in human melanoma.
SPATA2 (show SPATA2 Antibodies) has been described as a previously unrecognized factor in the linear ubiquitin chain assembly complex-dependent signaling pathways that serves as an adaptor between HOIP (show RNF31 Antibodies) and CYLD, thereby enabling recruitment of CYLD to signaling complexes.
The data reveal SPATA2 (show SPATA2 Antibodies) as a high-affinity binding partner of CYLD and HOIP (show RNF31 Antibodies), and a regulatory component of linear ubiquitin chain assembly complex-mediated NF-kappaB (show NFKB1 Antibodies) signaling.
The current investigations identified a subset of HPV-positive HNSCCs with mutations in the genes TRAF3 (show TRAF3 Antibodies) (tumor necrosis factor (show TNF Antibodies) receptor-associated factor 3) and CYLD (cylindromatosis lysine 63 deubiquitinase). Defects in TRAF3 (show TRAF3 Antibodies) and CYLD correlated with the activation of transcriptional factor nuclear factor kappaB, episomal HPV status of tumors, and improved patient survival.
The predicted PUB domain in the N-terminus of SPATA2 interacts with the USP domain of CYLD and SPATA2 is required for recruitment of CYLD to the TNF-alpha receptor-associated signaling complexes.
the role of CYLD in development, tissue homeostasis, and tumorigenesis
Findings provide physiological insight into the ciliary role of the CYLD/HDAC6 (show HDAC6 Antibodies) axis and suggest a functional interplay between these two proteins in ciliary homeostasis.
TLR4 (show TLR4 Antibodies) activates CASPASE-8 (show CASP8 Antibodies) to cleave and remove the deubiquitinase cylindromatosis (CYLD) in a TRIF (show RNF138 Antibodies)- and RIPK1 (show RIPK1 Antibodies)-dependent manner to disable necroptosis in macrophages.
CYLD contributes to the transdifferentiation of adventitial fibroblasts via deubiquitinating Nox4 (show NOX4 Antibodies) and may play a role in vascular remodeling.
this study shows that by polarization of the T cell cytokine response, CYLD can favor the development of allergic airway disease
Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis
Deubiquitinase CYLD negatively regulates MyD88 (show MYD88 Antibodies)-mediated signaling by directly interacting with MyD88 (show MYD88 Antibodies) and deubiquitinating nontypeable Haemophilus influenzae (NTHi)-induced K63-linked polyubiquitination of MyD88 (show MYD88 Antibodies) at lysine 231.
CYLD interrupts the ERK (show EPHB2 Antibodies)- and p38 (show CRK Antibodies)-/AP-1 (show JUN Antibodies) and c-Myc (show MYC Antibodies) pathways to suppress Nrf2 (show NFE2L2 Antibodies)-operated antioxidative capacity, thereby enhancing oxidative stress in the heart.
The crystal structures representing the catalytic states of zebrafish CYLD for Met1 (show DNMT1 Antibodies)- and Lys63-linked Ub chains and two distinct precatalytic states for Met1 (show DNMT1 Antibodies)-linked chains are presented.
This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
deubiquitinating enzyme CYLD
, probable ubiquitin carboxyl-terminal hydrolase CYLD
, ubiquitin carboxyl-terminal hydrolase CYLD
, ubiquitin specific peptidase like 2
, ubiquitin thioesterase CYLD
, ubiquitin thiolesterase CYLD
, ubiquitin-specific-processing protease CYLD
, cylindromatosis (turban tumor syndrome)
, probable ubiquitin carboxyl-terminal hydrolase CYLD-like
, retinitis pigmentosa 1 homolog